Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis

Li,Ji; Zhu,Jin-Xian; Zhang,Yu-Xin; Li,Shi-Qiang

doi:10.3892/ol.2024.14286

Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis

Authors:
- Ji Li
- Jin-Xian Zhu
- Yu-Xin Zhang
- Shi-Qiang Li
View Affiliations

Affiliations: Department of General Surgery, Chongqing Western Hospital, Chongqing 400051, P.R. China
Published online on: February 14, 2024 https://doi.org/10.3892/ol.2024.14286
Article Number: 153
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune checkpoint inhibitors (ICIs) have limited efficacy in mismatch repair proficient (pMMR) or metastatic microsatellite stable (MSS) advanced or metastatic colorectal cancer (mCRC). ICIs, in conjunction with tyrosine kinase inhibitors (TKIs) possessing anti‑angiogenic properties, serve as a potential strategy for circumventing the resistance exhibited by MSS or pMMR mCRC to immunotherapeutic interventions. The present study aimed to evaluate efficacy and safety of ICIs + TKIs and provide a reference for the treatment of CRC. The present systematic review and meta‑analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‑Analyses guidelines. PubMed, Embase, Cochrane, Web of Science and ClinicalTrials.gov databases were screened from January 1, 2003 to July 28, 2023. A total of 14 studies were included in qualitative and quantitative analyses, with a total of 819 patients enrolled. The Newcastle‑Ottawa scale scores of the 14 cohort studies included were ≥7, indicating they were of a high quality. The objective response rate (ORR) of ICIs + TKIs was 14% [95% confidence interval (CI), 0.08‑0.24; P=0.132] in patients with advanced or metastatic MSS/pMMR CRC. The disease control rate (DCR) was 65% (95% CI, 0.58‑0.74; P<0.0001). The overall incidence of adverse events of varying severity linked to combination of ICIs and TKIs in patients with advanced or metastatic MSS/pMMR CRC was 64% (95% CI, 0.52‑0.78; P<0.0001). The incidence of grade ≥3 adverse reactions was 24% (95% CI, 0.14‑0.4; P<0.0001). The sensitivity analysis indicated that the exclusion of individual studies did not yield statistically significant variations in combined analysis results. Based on the examination of publication bias, ORR and DCR, Begg's and Egger's tests had P‑values of 0.114 and 0.395, respectively. Overall publication bias overall was absent in the Begg's funnel plot, as there was no apparent asymmetry. Nonetheless, the P‑values of the Egger's and Begg's tests for adverse reactions and adverse reactions grade ≥3 were P=0.008 and P=0.048, respectively. The asymmetry of the Begg's funnel plots was evident, suggesting the presence of potential publication bias regarding adverse event results. In conclusion, the combination of ICIs and TKIs demonstrates a favorable effectiveness and notable safety profile in the management of patients with advanced or metastatic MSS/pMMR CRC.

View Figures

View References

1	Siegel RL, Wagle NS, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin. 73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
2	Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, et al: Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 34:10–32. 2023. View Article : Google Scholar : PubMed/NCBI
3	Ciombor KK and Bekaii-Saab T: A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer. Oncologist. 23:25–34. 2018. View Article : Google Scholar : PubMed/NCBI
4	Goel G: Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a ‘me too’ drug? Cancer Manag Res. 10:425–437. 2018. View Article : Google Scholar : PubMed/NCBI
5	Vogel A, Hofheinz RD, Kubicka S and Arnold D: Treatment decisions in metastatic colorectal cancer-beyond first and second line combination therapies. Cancer Treat Rev. 59:54–60. 2017. View Article : Google Scholar : PubMed/NCBI
6	Morris VK, Kennedy EB, Baxter NN, Benson AB III, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, et al: Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 41:678–700. 2023. View Article : Google Scholar : PubMed/NCBI
7	Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM and Hashemy SI: PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 110:312–318. 2019. View Article : Google Scholar : PubMed/NCBI
8	André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
9	Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B and Wu C: Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 121:809–818. 2019. View Article : Google Scholar : PubMed/NCBI
10	Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V and Masi G: Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability. Cancers (Basel). 14:49742022. View Article : Google Scholar : PubMed/NCBI
11	André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-Year follow-up from CheckMate 142. Ann Oncol. 33:1052–1060. 2022. View Article : Google Scholar : PubMed/NCBI
12	Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, et al: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, andomized, controlled trial. Lancet Oncol. 20:849–861. 2019. View Article : Google Scholar : PubMed/NCBI
13	Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, et al: Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 7:630–643. 2019. View Article : Google Scholar : PubMed/NCBI
14	Konecny GE: Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer. Lancet Oncol. 20:612–614. 2019. View Article : Google Scholar : PubMed/NCBI
15	Wu RY, Kong PF, Xia LP, Huang Y, Li ZL, Tang YY, Chen YH, Li X, Senthilkumar R, Zhang HL, et al: Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma. Clin Cancer Res. 25:4530–4541. 2019. View Article : Google Scholar : PubMed/NCBI
16	Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et al: Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 38:2053–2061. 2020. View Article : Google Scholar : PubMed/NCBI
17	Cousin S, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, Pernot S, Bellera C, Kind M, Auzanneau C, et al: Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): A single-arm, open-label, phase II trial. Clin Cancer Res. 27:2139–2147. 2021. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Zhang Z, Lou S, Li D, Ma Z and Xue L: Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study. Front Oncol. 12:9293422022. View Article : Google Scholar : PubMed/NCBI
19	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
20	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
21	Chen B, Zhao H, Huang J, Lv H, Xu W, Nie C, Wang J, Zhao J, He Y, Wang S and Chen X: Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. BMC Geriatr. 22:9872022. View Article : Google Scholar : PubMed/NCBI
22	Wang C, Chevalier D, Saluja J, Sandhu J, Lau C and Fakih M: Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer. Oncologist. 25:e1188–e1194. 2020. View Article : Google Scholar : PubMed/NCBI
23	He WZ, Wang L, Yin CX, Yi JH, Jin YN, Jiang C, Guo GF and Xia LP: Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. Cancer Med. 12:6488–6498. 2023. View Article : Google Scholar : PubMed/NCBI
24	Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC and Kim DW: A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 169:93–102. 2022. View Article : Google Scholar : PubMed/NCBI
25	Li J, Cong L, Liu J, Peng L, Wang J, Feng A, Yue J, Li L and Wang X and Wang X: The efficacy and safety of regorafenib in combination with anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer: A retrospective study. Front Oncol. 10:5941252020. View Article : Google Scholar : PubMed/NCBI
26	Ma S, Chen R, Duan L, Li C, Yang T, Wang J and Zhao D: Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: Results of a single-arm, single-center, prospective, phase II clinical study. J Gastrointest Oncol. 14:1052–1063. 2023. View Article : Google Scholar : PubMed/NCBI
27	Ren C, Mai ZJ, Jin Y, He MM, Wang ZQ, Luo HY, Zhang DS, Wu CY, Wang F and Xu RH: Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: A prospective, single-arm, open-label, phase II trial. Am J Cancer Res. 10:2946–2954. 2020.PubMed/NCBI
28	Sun L, Huang S, Li D, Mao Y, Wang Y and Wu J: Efficacy and safety of fruquintinib plus PD-1 inhibitors versus regorafenib plus PD-1 inhibitors in refractory microsatellite stable metastatic colorectal cancer. Front Oncol. 11:7548812021. View Article : Google Scholar : PubMed/NCBI
29	Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M and Liu MY: Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness. World J Gastrointest Oncol. 14:920–934. 2022. View Article : Google Scholar : PubMed/NCBI
30	Yang K, Han L, Wu S, Qu X, Li Q, Zhao C, Zhou J, Jin X, Wang Y, Yan D, et al: Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunol Immunother. 71:1443–1451. 2022. View Article : Google Scholar : PubMed/NCBI
31	Yu W, Tao Q, Zhang Y, Yi F and Feng L: Efficacy and safety of regorafenib combined with toripalimab in the third-line and beyond treatment of advanced colorectal cancer. J Oncol. 2021:99599462021. View Article : Google Scholar : PubMed/NCBI
32	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, et al: Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 5:1411–1420. 2019. View Article : Google Scholar : PubMed/NCBI
33	Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
34	Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
35	Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al: Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 44:698–711. 2016. View Article : Google Scholar : PubMed/NCBI
36	Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, et al: First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol. 40:161–170. 2022. View Article : Google Scholar : PubMed/NCBI
37	Wu Q, Wang Z, Luo Y and Xie X: Efficacy and safety of immune checkpoint inhibitors in proficient mismatch repair (pMMR)/non-microsatellite instability-high (non-MSI-H) metastatic colorectal cancer: A study based on 39 cohorts incorporating 1723 patients. BMC Immunol. 24:272023. View Article : Google Scholar : PubMed/NCBI
38	Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L and Carbone DP: Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 110:624–631. 2007. View Article : Google Scholar : PubMed/NCBI
39	Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Morisaki T and Katano M: The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 29:881–888. 2009.PubMed/NCBI
40	Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, et al: Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 12:17588359209568622020. View Article : Google Scholar : PubMed/NCBI
41	Chen Z and Jiang L: The clinical application of fruquintinib on colorectal cancer. Expert Rev Clin Pharmacol. 12:713–721. 2019. View Article : Google Scholar : PubMed/NCBI
42	Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, et al: Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 15:1635–1645. 2014. View Article : Google Scholar : PubMed/NCBI
43	Gu Y, Wang J, Li K, Zhang L, Ren H, Guo L, Sai Y, Zhang W and Su W: Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 74:95–115. 2014. View Article : Google Scholar : PubMed/NCBI
44	Xu X, Yu Y, Liu M, Liang L and Liu T: Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: A narrative review. Transl Cancer Res. 11:276–287. 2022. View Article : Google Scholar : PubMed/NCBI